Invalidity dossier
US 8178129
Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles and their use for diagnostic and therapy
Current assignee: Tel Aviv University Future Technology Development LP
Added 9/23/2026, 10:48:13 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview — US8178129B2
Title: Formulations of water insoluble or poorly water soluble drugs in lipidated glycosaminoglycan particles and their use for diagnostic and therapy
Patent number: US8178129B2 (application US11/718,485; pre-grant publication US20080248092A1)
Assignee: Tel Aviv University Future Technology Development L.P. (original and current assignee)
Inventors: Rimona Margalit, Noga Yerushalmi, Dan Peer, Ilia Rivkin
Key dates: Priority date 2004-11-02; filing date 2005-11-02; publication of application 2008-10-09; grant/publication of the patent 2012-05-15. Status listed as "Expired – Fee Related," with an adjusted expiration of 2028-05-29. A reassignment to Tel-Aviv University Future Technology Development L.P. was recorded 2012-02-23.
Purpose: The patent addresses delivery of drugs that are water insoluble or poorly water soluble. Such drugs are difficult to formulate in aqueous systems; the disclosed approach packages them in lipidated glycosaminoglycan particles, aiming at drug delivery for diagnostic and therapeutic uses (including anticancer/cytotoxic agents such as paclitaxel).
Plain-language scope: According to the supplied text, the invention concerns formulations in which a poorly soluble active ingredient is carried in particles made of a glycosaminoglycan (for example hyaluronan, heparin, heparan sulfate, chondroitin sulfate, keratan sulfate or dermatan) that has been modified with lipid components (for example phosphatidylethanolamine). The text associates these particles with methods of making the formulation (mixing, solvent handling, centrifugation, evaporation), pharmaceutical compositions, suspensions, buffers, diluents and excipients, and with sustained release, injection and targeting of hyaluronan receptors. Numerical claims references are not available in the excerpt, so individual claim language cannot be quoted.
What the excerpt does not establish: It does not provide the full claims, the complete description, the written description or examples, claim-by-claim scope, priority-chain details beyond those listed, the specific drugs or lipids claimed, or the reason for the fee-related expiration. No litigation, ownership-transfer, validity or prior-art matter is addressed here.
Source: https://patents.google.com/patent/[US8178129](/patent/US8178129)/en
Generated 10/1/2026, 9:54:07 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 8178129. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.